Intercept Pharmaceuticals (ICPT) Posts Earnings Results, Misses Estimates By $0.86 EPS

Intercept Pharmaceuticals (NASDAQ:ICPT) issued its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($4.43) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($3.57) by ($0.86), Bloomberg Earnings reports. Intercept Pharmaceuticals had a negative return on equity of 176.51% and a negative net margin of 344.74%. The company had revenue of $37.69 million for the quarter, compared to the consensus estimate of $39.01 million. During the same quarter last year, the business earned ($4.84) earnings per share. Intercept Pharmaceuticals’s revenue was up 173.1% compared to the same quarter last year.

Intercept Pharmaceuticals (NASDAQ:ICPT) traded up $2.61 during midday trading on Thursday, hitting $56.02. The stock had a trading volume of 1,447,000 shares, compared to its average volume of 1,107,216. The company has a market capitalization of $1,490.00, a P/E ratio of -4.24 and a beta of -2.13. Intercept Pharmaceuticals has a 52-week low of $51.05 and a 52-week high of $135.59. The company has a debt-to-equity ratio of 3.15, a quick ratio of 5.95 and a current ratio of 5.95.

ICPT has been the subject of a number of research analyst reports. Wedbush reiterated a “buy” rating and issued a $253.00 target price on shares of Intercept Pharmaceuticals in a report on Friday, January 5th. Deutsche Bank initiated coverage on Intercept Pharmaceuticals in a report on Tuesday, December 12th. They issued a “buy” rating and a $106.00 target price for the company. Goldman Sachs Group downgraded Intercept Pharmaceuticals from a “neutral” rating to a “sell” rating in a report on Wednesday, February 7th. Zacks Investment Research upgraded Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 16th. Finally, Laidlaw upgraded Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $90.00 target price for the company in a report on Wednesday, November 1st. Five equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have assigned a buy rating to the company. Intercept Pharmaceuticals has an average rating of “Hold” and a consensus target price of $132.14.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ICPT. Alliancebernstein L.P. increased its holdings in shares of Intercept Pharmaceuticals by 6.2% during the second quarter. Alliancebernstein L.P. now owns 9,459 shares of the biopharmaceutical company’s stock valued at $1,145,000 after acquiring an additional 550 shares in the last quarter. Teachers Advisors LLC increased its holdings in shares of Intercept Pharmaceuticals by 16.1% during the second quarter. Teachers Advisors LLC now owns 18,430 shares of the biopharmaceutical company’s stock valued at $2,231,000 after acquiring an additional 2,559 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Intercept Pharmaceuticals by 23.3% during the second quarter. PNC Financial Services Group Inc. now owns 2,490 shares of the biopharmaceutical company’s stock valued at $302,000 after acquiring an additional 470 shares in the last quarter. Northern Trust Corp increased its holdings in shares of Intercept Pharmaceuticals by 14.9% during the second quarter. Northern Trust Corp now owns 84,983 shares of the biopharmaceutical company’s stock valued at $10,289,000 after acquiring an additional 10,993 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Intercept Pharmaceuticals by 4.5% during the second quarter. Vanguard Group Inc. now owns 1,328,133 shares of the biopharmaceutical company’s stock valued at $160,797,000 after acquiring an additional 57,149 shares in the last quarter. Hedge funds and other institutional investors own 75.48% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.americanbankingnews.com/2018/02/14/intercept-pharmaceuticals-icpt-releases-earnings-results-misses-expectations-by-1-04-eps.html.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Earnings History for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply